Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R V Giles

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Current Opinion in Molecular Therapeutics|March 16, 2001
Antisense oligonucleotide technology: from EST to therapeuticsR V Giles
Anti-Cancer Drug Design|February 1, 1992
Enhanced RNase H activity with methylphosphonodiester/phosphodiester chimeric antisense oligodeoxynucleotidesR V Giles, D M Tidd
Nucleic Acids Research|February 25, 1992
Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structuresR V Giles, D M Tidd
Anti-Cancer Drug Design|February 1, 1993
Chimeric oligodeoxynucleotide analogues: enhanced cell uptake of structures which direct ribonuclease H with high specificityR V Giles, D G Spiller, D M Tidd
Antisense Research and Development|January 1, 1995
Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotidesR V Giles, D G Spiller, D M Tidd
Antisense & Nucleic Acid Drug Development|June 4, 1999
Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNAR V Giles, D G Spiller, R E Clark, et al.
Nucleosides & Nucleotides|November 5, 1999
Identification of a good c-myc antisense oligodeoxynucleotide target site and the inactivity at this site of novel NCH triplet--targeting ribozymesR V Giles, D G Spiller, R E Clark, et al.
BMC Molecular Biology|December 6, 2001
Expression of c-myc is not critical for cell proliferation in established human leukemia linesD M Tidd, R V Giles, C M Broughton, et al.
Blood|June 17, 1998
Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugationD G Spiller, R V Giles, J Grzybowski, et al.
Blood|July 15, 1995
Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNAR V Giles, D G Spiller, J A Green, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Current Opinion in Molecular Therapeutics|March 16, 2001
Antisense oligonucleotide technology: from EST to therapeuticsR V Giles
Anti-Cancer Drug Design|February 1, 1992
Enhanced RNase H activity with methylphosphonodiester/phosphodiester chimeric antisense oligodeoxynucleotidesR V Giles, D M Tidd
Nucleic Acids Research|February 25, 1992
Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structuresR V Giles, D M Tidd
Anti-Cancer Drug Design|February 1, 1993
Chimeric oligodeoxynucleotide analogues: enhanced cell uptake of structures which direct ribonuclease H with high specificityR V Giles, D G Spiller, D M Tidd
Antisense Research and Development|January 1, 1995
Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotidesR V Giles, D G Spiller, D M Tidd
Antisense & Nucleic Acid Drug Development|June 4, 1999
Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNAR V Giles, D G Spiller, R E Clark, et al.
Nucleosides & Nucleotides|November 5, 1999
Identification of a good c-myc antisense oligodeoxynucleotide target site and the inactivity at this site of novel NCH triplet--targeting ribozymesR V Giles, D G Spiller, R E Clark, et al.
BMC Molecular Biology|December 6, 2001
Expression of c-myc is not critical for cell proliferation in established human leukemia linesD M Tidd, R V Giles, C M Broughton, et al.
Blood|June 17, 1998
Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugationD G Spiller, R V Giles, J Grzybowski, et al.
Blood|July 15, 1995
Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNAR V Giles, D G Spiller, J A Green, et al.
Pageof 2